These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15306836)

  • 21. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. At last, a weight neutral insulin?
    Fritsche A; Häring H
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S41-6. PubMed ID: 15306837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basal insulins: Pharmacological properties and patient perspectives.
    Abrahamson MJ
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
    Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin detemir, does a new century bring a better basal insulin?
    Hordern SV; Russell-Jones DL
    Int J Clin Pract; 2005 Jun; 59(6):730-9. PubMed ID: 15924603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unlocking the opportunity of tight glycaemic control. Far from goal.
    Del Prato S
    Diabetes Obes Metab; 2005 Nov; 7 Suppl 1():S1-4. PubMed ID: 16135133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen.
    Mohn A; Strang S; Wernicke-Panten K; Lang AM; Edge JA; Dunger DB
    Diabetes Care; 2000 Apr; 23(4):557-9. PubMed ID: 10857953
    [No Abstract]   [Full Text] [Related]  

  • 37. Insulin analogues: have they changed insulin treatment and improved glycaemic control?
    Madsbad S
    Diabetes Metab Res Rev; 2002; 18 Suppl 1():S21-8. PubMed ID: 11921426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of basal insulin.
    Shah VN; Moser EG; Blau A; Dhingra M; Garg SK
    Diabetes Technol Ther; 2013 Sep; 15(9):727-32. PubMed ID: 23965036
    [No Abstract]   [Full Text] [Related]  

  • 39. Newer basal insulin analogues: degludec, detemir, glargine.
    Kalra S
    J Pak Med Assoc; 2013 Nov; 63(11):1442-4. PubMed ID: 24392539
    [No Abstract]   [Full Text] [Related]  

  • 40. The past, present, and future of basal insulins.
    Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
    Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.